Amiodarone and beta blockade - is the whole better than parts?

Ghuran AV, Camm AJ
Amiodarone and Beta Blockade – is the Whole Better than Parts?

A. V. Ghuran, A. J. Camm

Amiodarone and beta-blockers are the two most widely used antiarrhythmic drugs. Although these agents share similar properties, they also have distinct pharmacological, pharmacokinetic and electrophysiological differences. Recent data suggest that when these agents are given as a combination, a synergistic interaction can occur with a beneficial effect on clinical outcome. Although the exact nature of this interaction remains unknown, the individual characteristics of one agent may be protective under conditions, which may negate or prevent the other agent from being effective. The purpose of this article is to review some of the individual differences between these two drugs that may explain their synergistic interaction when combined. J Clin Basic Cardiol 2000; 3: 205–7.

Key words: amiodarone, beta-blockers, mortality

The last century has witnessed remarkable and significant progress in the field of pharmacological and non-pharmacological therapies in cardiac arrhythmology. Two outstanding pharmacological agents that have contributed to these advances are beta-blockers and amiodarone. In contrast to other antiarrhythmic agents, large-scale randomised and meta-analysis studies have shown that these agents can significantly reduce cardiac arrhythmic mortality [1–6]. Moreover, beta-blockers have been shown undisputedly to produce a substantial reduction in all cause mortality [7, 8] whilst amiodarone has a neutral effect [3, 4] except in meta-analysis when a small (13 %) but significant reduction of mortality has been noted [6]. Although these agents share similar properties, they also have distinct pharmacokinetic and electrophysiological differences. Recent data [9–11] suggest that when these agents are given as a combination, a synergistic interaction can occur with a beneficial effect on clinical outcome. Although the exact nature of this interaction remains unknown, the individual characteristics of one agent may be protective under conditions, which may negate or prevent the other agent from being effective. For instance, long-term treatment with beta-blockers can induce a significant increase in the number of beta-adrenoceptors, which may explain a beneficial interaction when one agent is working sub-optimally. For instance, long-term treatment with beta-blockers can induce a significant increase in the number of beta-adrenoceptors, which may explain the hyperadrenergic state frequently observed following the sudden withdrawal of drug therapy [16]. The addition of amiodarone under these circumstances may attenuate this effect.

Effects of Adrenergic Stimulation

Hyperadrenergic states and ischaemia play an important role in the genesis of ventricular arrhythmias, especially in patients with impaired left ventricular function. Amongst other actions adrenergic stimulation can: (1) increase inward calcium currents, potentiating delayed after depolarisations; (2) influence the pacemaker current thereby increasing automaticity of cardiac cells; (3) augment the delayed rectifier potassium current (in particular the Iks component), shortening action potential duration and refractoriness; and (4) enhance the sodium inward current, reversing the effects of class I agents [18]. Beta-blockers antagonise these effects of adrenergic stimulation, have anti-ischaemic properties and can improve left ventricular dysfunction [19, 20]. In addition, beta-blockers can abolish the circadian variation of myocardial ischaemia and sudden cardiac death, as well as raise the threshold for ventricular fibrillation [18].

Pharmacology of Amiodarone

Amiodarone has a complex pharmacological profile and can inhibit sodium, potassium (Ikr and Iks) and calcium currents (IcaL). Amiodarone has a greater inhibitory effect on Ikr channels than on Iks channels. Its major antiarrhythmic properties are thought to be related to prolongation of the action potential duration. Amiodarone also exerts an anti-adrenergic effect by not competitively inhibiting alpha- and beta-receptors [14]. Unlike beta-blockers, amiodarone does not bind to the catecholamine recognition site of the beta-receptor and appears to induce a significant decrease in the number of beta-adrenoceptors [15]. In addition, amiodarone also inhibits the coupling of beta-receptors with the regulatory unit of adenylate cyclase [16]. These properties combine to inhibit the stimulated activity of adenylate cyclase but not its basal activity. This effect is different from adreno-receptor beta-blockers, which can inhibit both basal and stimulated activities of adenylate cyclase [14]. Amiodarone can reduce the cardiac chronotropic and inotropic responses to glucagon, whilst beta-blockers (propranolol) cannot [17]. Therefore, amiodarone has independent, distinct anti-adrenergic properties over and above those of conventional beta-blockers, which may explain a beneficial interaction when one agent is working sub-optimally. For instance, long-term treatment with beta-blockers can induce a significant increase in the number of beta-adrenoceptors, which may explain the hyperadrenergic state frequently observed following the sudden withdrawal of drug therapy [16]. The addition of amiodarone under these circumstances may attenuate this effect.

Amiodarone and Beta-Blocker

Experimental studies have shown that the effect of amiodarone on action potential duration is significantly reduced when co-administered with isoproterenol [13]. However, the prolongation of action potential duration still remains...
significantly lengthened when compared to baseline values. Nevertheless, this reduction in action potential duration may have clinical implications by reducing the efficacy of amiodarone in terminating or preventing ventricular tachyarrhythmias. Furthermore, amiodarone can significantly prolong sinus cycle length, which can be fully reversed when isoproterenol is co-administered [13]. Increased heart rate is a marker of left ventricular dysfunction or hyperadrenergic state and is a poor prognostic marker in patients with heart failure [21, 22] and in the post myocardial infarction period [23]. In addition, during the first 5–10 minutes of myocardial ischaemia, an increased heart rate can change the action potential upstroke characteristics (brought about by rate dependent changes in intracellular sodium and calcium ion concentrations), leading to a reduction in conduction velocity. This rate dependent conduction slowing is an important mechanism in the genesis of re-entry arrhythmias in the early peri-infarction period [24]. Therefore, the failure of amiodarone to maintain a sufficiently slow heart rate, especially during periods of ischaemia or hyperadrenergic states may consequently lead to ventricular tachyarrhythmias and sudden cardiac death. The addition of a beta-blocker under these conditions can therefore maintain the efficacy of amiodarone.

These theoretical considerations are supported by data derived from CAMIAT and EMIAT [9–11]. CAMIAT demonstrated a significant reduction in arrhythmic mortality but not in all cause mortality. Subgroup analysis showed a greater reduction in sudden cardiac death in patients with heart rates greater than 70 beats/minute when amiodarone was co-administered with a beta-blocker (Figure 1). EMIAT also showed a significant reduction in arrhythmic but not all cause mortality. Intention to treat analysis of 2-year total cardiac mortality showed a significant reduction in sudden cardiac death. PI = placebo, Am = amiodarone, BB = beta-blockers.

Figure 1. Subgroup analysis data from CAMIAT [9]. Note, the addition of a beta-blocker to amiodarone markedly reduced all cause (ACM) and sudden cardiac death (SCD) mortality, particularly in patients with heart rates greater than 70 beats/minute. PI = placebo, Am = amiodarone, BB = beta-blockers.

In summary, beta-adrenergic stimulation can markedly modulate the electrophysiological actions of antiarrhythmic agents and could create a milieu that is proarrhythmic. The independent pharmacological properties of beta-blockers and amiodarone can interact synergistically to protect, when either drug alone lacks an efficacious effect. Until the results of larger prospective randomised studies are available, the current clinical evidence of this beneficial interaction derived from CAMIAT and EMIAT meta-analysis. Reproduced with permission from Boutitie et al. [11].

**Conclusion**

In summary, beta-adrenergic stimulation can markedly modulate the electrophysiological actions of antiarrhythmic agents and could create a milieu that is proarrhythmic. The independent pharmacological properties of beta-blockers and amiodarone can interact synergistically to protect, when either drug alone lacks an efficacious effect. Until the results of larger prospective randomised studies are available, the current clinical evidence of this beneficial interaction derived from CAMIAT and EMIAT meta-analysis. Reproduced with permission from Boutitie et al. [11].
from post hoc analysis data, indicate that amiodarone should not replace a beta-blocker or vice versa, but where indicated, these agents should be prescribed together.

References

Mitteilungen aus der Redaktion

Besuchen Sie unsere zeitschriftenübergreifende Datenbank

- Bilddatenbank
- Artikeldatenbank
- Fallberichte

e-Journal-Abo
Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.

Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.

Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

☑ Bestellung e-Journal-Abo

Haftungsausschluss

Bitte beachten Sie auch diese Seiten:

- Impressum
- Disclaimers & Copyright
- Datenschutzerklärung